Every earnings call for ORCHPHARMA — management tone, guidance, KPIs and promise tracking, quarter by quarter.
ORCHPHARMA · 7 transcripts · Healthcare · latest Q4 FY26Orchid Pharma Limited has 7 earnings calls on record here, a Healthcare company, most recently Q4 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
FY26 Revenue ₹811 cr (−12% YoY); FY26 EBITDA ₹101 cr (−35% YoY). Q4 FY26 standalone revenue stable at INR238 crores, up 0.42% YoY.
Read full transcript & analysisEBITDA (9-month FY26) ₹58 cr (−50% YoY); EBITDA Margin (Q3 FY26) 6%; Gross Margin (Q3 FY26) 31%. Sales stood at INR 207 crores for Q3 FY26.
Read full transcript & analysisEBITDA ₹6 cr. Q2 FY26 sales stood at ₹194 crores, representing a decline of approximately 13% year-on-year.
Read full transcript & analysisGross Margin 42%. Q1 FY26 sales stood at INR 173 crores, a steep decline of approximately 29% compared to INR 244 crores in the same period last year.
Read full transcript & analysisRevenue ₹237 cr (+9% YoY); EBITDA ₹40 cr. Q4 FY25 sales reached Rs. 237 crores, marking a 9% increase year-over-year.
Read full transcript & analysisEBITDA ₹37 cr; PAT (9M FY25) ₹78 cr (+26% YoY); Total Income ₹227 cr. Q3 FY25 Total Income: INR227 crores.
Read full transcript & analysisQ2 FY25 Sales ₹223 cr; Q2 FY25 EBITDA ₹38 cr; H1 FY25 Sales ₹467 cr (+22% YoY). Q2 FY25 sales reached INR222.7 crores, with EBITDA at INR37.5 crores.
Read full transcript & analysis